NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
13 trialsNCT07189065 2025-12-16
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2 Recruiting
NCT06561347 2025-11-24
ZEBRA
Massachusetts General Hospital
Phase 2 Recruiting
NCT07208981 2025-10-06
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04083495 2025-09-22
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT04587687 2025-04-24
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
University of California, Davis
Phase 2 Recruiting
NCT04792489 2025-04-24
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT05914662 2024-08-28
ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05868395 2024-05-29
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Medical University of Vienna
Phase 2 Recruiting
NCT06415708 2024-05-16
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT04510636 2024-03-22
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
University Health Network, Toronto
Phase 2 Recruiting
NCT05848765 2023-11-29
REFRACT
University of Birmingham
Phase 2 Recruiting
NCT06136351 2023-11-29
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Recruiting